Marko Korenjak serves as a Civil Society Representative on the Management Board of the European Medicines Agency (EMA). He previously served on EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) and as Co-Chair of the Patients’ and Consumers’ Working Party (PCWP). He has also contributed to the DIA Advisory Council for Europe, Middle East & Africa (ACEMEA) and remains active in the WHO EURO Collaborating Committee on TB, HIV, and viral hepatitis, as well as in the EU working group on monitoring hepatitis B and C. Marko is a member of the HERA Civil Society Advisory Forum. He holds three Master’s degrees—in Business and Economy, International Relations and Diplomacy, and International Patient Advocacy. As President of ELPA, he leads a team engaged in 20 EU Horizon projects, managing over €200 million in liver-related research. In 2017, The Economist recognized him among the 18 most influential individuals in hepatitis elimination, and in 2024 he received PFMD’s Made with Patients award.